HC Wainwright Forecasts Kamada’s Q1 Earnings (NASDAQ:KMDA)

Kamada Ltd. (NASDAQ:KMDA) – HC Wainwright issued their Q1 2025 earnings per share estimates for shares of Kamada in a report issued on Thursday, March 6th. HC Wainwright analyst A. Fein anticipates that the biotechnology company will post earnings per share of $0.07 for the quarter. HC Wainwright has a “Buy” rating and a $11.00 price objective on the stock. The consensus estimate for Kamada’s current full-year earnings is $0.23 per share. HC Wainwright also issued estimates for Kamada’s Q2 2025 earnings at $0.06 EPS, Q3 2025 earnings at $0.04 EPS, Q4 2025 earnings at $0.11 EPS and FY2029 earnings at $0.80 EPS.

Kamada Stock Up 3.1 %

KMDA opened at $7.32 on Friday. The stock’s fifty day moving average is $7.08 and its two-hundred day moving average is $6.14. The company has a market capitalization of $420.75 million, a P/E ratio of 26.14, a PEG ratio of 0.97 and a beta of 0.99. Kamada has a 52 week low of $4.74 and a 52 week high of $9.15.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Geode Capital Management LLC increased its holdings in shares of Kamada by 5.6% in the 4th quarter. Geode Capital Management LLC now owns 29,289 shares of the biotechnology company’s stock valued at $178,000 after acquiring an additional 1,549 shares during the period. Aristides Capital LLC increased its holdings in shares of Kamada by 12.1% in the 4th quarter. Aristides Capital LLC now owns 63,485 shares of the biotechnology company’s stock valued at $387,000 after acquiring an additional 6,850 shares during the period. NewEdge Advisors LLC increased its holdings in shares of Kamada by 54.2% in the 4th quarter. NewEdge Advisors LLC now owns 23,496 shares of the biotechnology company’s stock valued at $143,000 after acquiring an additional 8,260 shares during the period. JPMorgan Chase & Co. purchased a new position in shares of Kamada in the 4th quarter valued at $67,000. Finally, Public Employees Retirement System of Ohio purchased a new position in shares of Kamada in the 3rd quarter valued at $77,000. 20.38% of the stock is currently owned by hedge funds and other institutional investors.

About Kamada

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.